Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes

References

• ANTONUCCI, T., McLAux, R., WorrcomE, R. et al., 1997, Impaired glucose tolerance is normalized by treatment with the thiazoldinedione, troglitazone. Diabetes Care, 20, 188–193.
   Google Scholar
• BURGESS, S. J., SINGER, G. G. and BRENNAN, D. C., 1998, Effect of troglitazone on cyclosporine whole blood levels. Transplantation, 66, 1399–1400.
   Google Scholar
• CAVAGHAN, M. K., EHRMANN, D. A., BYRNE, M. M. et at., 1997, Treatment with oral antidiabetic agent troglitazone improves /3 cell responses to glucose in subjects with impaired glucose tolerance. Journal of Clinical Investigation, 100, 530–537.
   Google Scholar
• COWIE, C. C. and EBERHARDT, M. S. (eds), 1996, Diabetes 1996 Vital Statistics (Alexandria: American Diabetes Association).
   Google Scholar
• DUNNETT, G. W., 1964, New tables for multiple comparisons with a control. Biometrics 20, 482-491. FUJIWARA, T., YOSHIOKA, U. et at., 1998, Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes, 37, 1549–1558.
   Google Scholar
• KAPLAN, B., FRIEDMAN, G., JAcoEs, M. et al., 1998, Potential interaction of troglitazone and cyclo spo rine. Transplantation, 65, 1399–1400.
   Google Scholar
• KUMAR, S., BOULTON, A. J. M., BECK-NIELSEN, H. et al., 1996, Troglitazone, an insulin action enhancer, improves metabolic control in type II diabetes patients. Diabetelogia, 39, 701–709.
   Google Scholar
• LECLUYSE, E. L., BULLOCK, P. and PARKINSON, A., 1996b, Strategies for restoration and maintenance of normal hepatic structure and function in long-term cultures of rat hepatocytes. Advanced Drug Delivery Reviews, 22, 133–186.
   Web of Science ®Google Scholar
• LECLUYSE, E. L., BULLOCK, P., PARKINSON, A. and HOCHMAN, J. H., 1996a, Cultured rat hepatocytes. In R. T. Borchardt, G. Wilson and P. Smith (eds), Model Systems for Biopharmaceutical Assessment of Drug Absorption and Metabolism (New York: Plenum), pp. 121–159.
   Google Scholar
• LEHMANN, J. M., McKEE, D. D., WATSON, M. A., WILLSON, T. M., MOORE, J. T. and KLIEWER, S. A., 1998, The human orphan nuclear receptor PXR is activated by compounds that regulate C Y P3 A 4 gene expression and cause drug interactions. Journal of Clinical Investigation, 102, 1016–1023.
   PubMed Web of Science ®Google Scholar
• LEHMANN, J. M., MOORE, L. B., SMITTI -OLIVER, T. A. et al., 1995, An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor y (PPAR y). Journal of Biological Chemistry, 270, 12953–12956.
   Google Scholar
• KOCAREK, T. A., SCHUETZ, E. G., STROM, S. C., FISHER, R. A. and GUZELIAN, P. S., 1995, Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes. Drug Metabolism and Disposition, 23, 415–421.
   PubMed Web of Science ®Google Scholar
• KOUP, J. R., ANDERSON, G. and DTI, C. M., 1998, Effect of troglitazone on urinary excretion of cortisol and 6/3-hydroxycortisol. Journal of Clinical Pharmacology, 38, 815–818.
   PubMed Web of Science ®Google Scholar
• LOI, C. M., KNOWLTON, P. W., STERN, R. et al., 1998a, Effect of troglitazone on steady-state pharmacokinetics of digoxin. Journal of Clinical Pharmacology, 38, 178–183.
   Google Scholar
• LOI, C. M., MALCOLM, Y. RANDINTTIS, E. et al., 1999a, Clinical pharmacokinetics of Troglitazone. Clinical Pharmacokinetics, 37, 91–104.
   Google Scholar
• LOI, C. M., STERN, R., ABEL, R. et al., 1999b, Effect of troglitazone on pharmacokinetics and pharmacodynamics of atorvastatin. Clinical Pharmacology and Therapeutics, 65, PII139.
   Google Scholar
• LOI, C. M., STERN, R., VASSOS, A. B. et al., 1998b, Effect of troglitazone on terfena dine pharmacokinetics. Clinical Pharmacology and Therapeutics, 63, 228.
   Google Scholar
• LOI, C. M., KOUP, J. R., VASSOS, A. B. and SEDMAN, A. J., 1999c, Effect of TRZ on fexofenadine pharmacokonetics. Clinical Pharmacology and Therapeutics, 65, PI1140.
   Google Scholar
• LOI, C. M., STERN, R., KOUP, J. R. et al., 1999d, Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent. Journal of Clinical Pharmacology, 39, 410–414.
   Google Scholar
• MORRIS, D. L. and DAVILA, J. C., 1996, Analysis of rat cytochrome P450 isoenzyme expression using semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). Biochemical Phar-macology, 52, 781–792.
   PubMed Web of Science ®Google Scholar
• MUNTANE -RELAT, J., OuRuN, J. C., DOMERGUE, J. and MAUREL, P., 1995, Differential effects of cytokines on the inducible expression of CYP1A1, CYP 1A2 and CYP3A4 in human hepatocytes in primary culture. Hepatology, 22, 1143–1153.
   Google Scholar
• OMIESINSKI, C. J., HASSETT, C. and COSTA, P., 1990, Developmental expression and in situ localization of the phenobarbital-inducible rat hepatic mRNAs for cytochromes CYP2B1, CYP2B2, CYP2C6 and CYP3A1. Molecular Pharmacology, 38, 462–470.
   PubMedGoogle Scholar
• PARKINSON, A., 1996, Biotransformation of xenobiotics. In C. D. Klaassen (ed.), Casarett and Doull's Toxicology. The Basic Science of Poisons, 5th edn (New York: McGraw-Hill), pp. 113–186.
   Google Scholar
• PARKINSON, A. and GEMZIK, B., 1991, Production and purification of antibodies against rat liver P450 enzymes. Methods in Enzymology, 206, 233–245.
   PubMed Web of Science ®Google Scholar
• PEARCE, R. E., MCINTYRE, C. J., MADAN, A., SANZGIRI U., DRAPER, A. J., BULLOCK, P. L., COOK, D. C., BURTON, L. A., LATHAM, J., NEVINS, C. and PARKINSON, A., 1996, Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Archives of Biochemistry and Biophysics, 331, 145–169.
   Google Scholar
• REZULIN ® PRODUCT LABELLING (package insert), 1998, Warner-Lambert Co. (Morris Plains, NJ, USA).
   Google Scholar
• SIDHU, J. S., FARIN, F. M. and OMIECINSKI, C. J., 1993, Influence of extracellular matrix overlay on phenobarbital-mediated induction of CYP2B1, 2B2, and 3A1 genes in primary adult rat hepatocyte culture. Archives of Biochemistry and Biophysics, 30, 103–113.
   Google Scholar
• STROM S. C., PISAROV, L. A., DOAK°, K., THOMPSON, M. T., SCHUETZ J. D. and SCHUETZ, E. G., 1996, Use of human hepatocytes to study P450 gene induction. Methods in Enzymology, 272, 388–401.
   Google Scholar
• VIDAL -Pum, A., JIMINEZ -LIMAN, M., LOWELL, B. B. et at., 1996, Regulation of PPARy gene expression by nutrition and obesity in rodents. Journal of Clinical Investigation, 97, 2553–2561.
   Google Scholar
• WORTELBOER, H. M., DE KRUIF, C. A,. VAN IERSEL, A. A. J., FALKE, H. E., NOORDHOEK, J. and BLAAUBOER, B. J., 1990, The isoenzyme pattern of cytochrome P450 in rat hepatocytes in primary culture, comparing different enzyme activities in microsomal incubations and in intact mono-layers. Biochemical Pharmacology, 40, 2525–2534.
   Google Scholar
• YOUNG, M. A., LETTIS, S. and EASTMOND, R., 1998, Concomitant administration of cholestyramine influences the absorption of troglitazone. British Journal of Clinical Pharmacology, 45, 37–40.
   PubMed Web of Science ®Google Scholar